Generics in France

November 2019 | 42 pages | ID: GD1EF4ABE3BEN
MarketLine

Abstracts

Generics in France

SUMMARY

Generics in France industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

KEY HIGHLIGHTS

• For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
• The French generics market had total revenues of $4.2bn in 2018, representing a compound annual growth rate (CAGR) of 1.7% between 2014 and 2018.
• Market consumption volume increased with a CAGR of 1.4% between 2014 and 2018, to reach 81% of total pharma volume 2018.
• The French market has been relatively slow to adopt generics compared to other European countries, such as the UK and Germany. Recent changes to policies have meant that a slow uptake has been possible, and the value of the market has increased.

SCOPE

• Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in France
• Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in France
• Leading company profiles reveal details of key generics market players’ global operations and financial performance
• Add weight to presentations and pitches by understanding the future growth prospects of the France generics market with five year forecasts by both value and volume

REASONS TO BUY

• What was the size of the France generics market by value in 2018?
• What will be the size of the France generics market in 2023?
• What factors are affecting the strength of competition in the France generics market?
• How has the market performed over the last five years?
• How large is France’s generics market in relation to its regional counterparts?

Contents

1 EXECUTIVE SUMMARY

1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape

2 MARKET OVERVIEW

2.1. Market definition
2.2. Market analysis

3 MARKET DATA

3.1. Market value
3.2. Market volume

4 MARKET SEGMENTATION

4.1. Geography segmentation

5 MARKET OUTLOOK

5.1. Market value forecast
5.2. Market volume forecast

6 FIVE FORCES ANALYSIS

6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry

7 COMPETITIVE LANDSCAPE

7.1. Who are the leading players?
7.2. Which players have been most successful in the recent past (1-3 years)?
7.3. What mergers or acquisitions have taken place in the last year?

8 COMPANY PROFILES

8.1. Teva Pharmaceutical Industries Limited
8.2. Pfizer Inc.
8.3. Sanofi SA
8.4. Les Laboratoires Servier

9 MACROECONOMIC INDICATORS

9.1. Country data

10 APPENDIX

10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine

List Of Tables

LIST OF TABLES

Table 1: France generics market value: $ million, 2014-18
Table 2: France generics market volume: % of total pharma, 2014-18
Table 3: France generics market geography segmentation: $ million, 2018
Table 4: France generics market value forecast: $ million, 2018-23
Table 5: France generics market volume forecast: % of total pharma, 2018-23
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Pfizer Inc.: key facts
Table 10: Pfizer Inc.: Annual Financial Ratios
Table 11: Pfizer Inc.: Key Employees
Table 12: Pfizer Inc.: Key Employees Continued
Table 13: Sanofi SA: key facts
Table 14: Sanofi SA: Annual Financial Ratios
Table 15: Sanofi SA: Key Employees
Table 16: Sanofi SA: Key Employees Continued
Table 17: Les Laboratoires Servier: key facts
Table 18: Les Laboratoires Servier: Key Employees
Table 19: France size of population (million), 2014-18
Table 20: France gdp (constant 2005 prices, $ billion), 2014-18
Table 21: France gdp (current prices, $ billion), 2014-18
Table 22: France inflation, 2014-18
Table 23: France consumer price index (absolute), 2014-18
Table 24: France exchange rate, 2014-18

List Of Figures

LIST OF FIGURES

Figure 1: France generics market value: $ million, 2014-18
Figure 2: France generics market volume: % of total pharma, 2014-18
Figure 3: France generics market geography segmentation: % share, by value, 2018
Figure 4: France generics market value forecast: $ million, 2018-23
Figure 5: France generics market volume forecast: % of total pharma, 2018-23
Figure 6: Forces driving competition in the generics market in France, 2018
Figure 7: Drivers of buyer power in the generics market in France, 2018
Figure 8: Drivers of supplier power in the generics market in France, 2018
Figure 9: Factors influencing the likelihood of new entrants in the generics market in France, 2018
Figure 10: Factors influencing the threat of substitutes in the generics market in France, 2018
Figure 11: Drivers of degree of rivalry in the generics market in France, 2018

COMPANIES MENTIONED

Teva Pharmaceutical Industries Limited
Pfizer Inc.
Sanofi SA
Les Laboratoires Servier